Analysts Set CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Price Target at $9.56

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $9.5625.

Several analysts have commented on CAMP shares. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Piper Sandler restated an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $5.00 to $9.00 in a report on Tuesday, June 16th.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $4.25 on Friday. The company’s fifty day moving average is $4.12 and its two-hundred day moving average is $4.35. CAMP4 Therapeutics has a 1 year low of $2.20 and a 1 year high of $7.75. The company has a market capitalization of $266.70 million, a P/E ratio of -1.83 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, equities analysts expect that CAMP4 Therapeutics will post -0.57 earnings per share for the current year.

Insider Transactions at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, CFO Kelly Gold acquired 10,000 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was purchased at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares in the company, valued at $39,600. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Andrew Schwab sold 400,000 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders purchased 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CAMP. Bridgeway Capital Management LLC acquired a new position in shares of CAMP4 Therapeutics in the second quarter worth $36,000. Jefferies Financial Group Inc. acquired a new stake in CAMP4 Therapeutics during the fourth quarter valued at $70,000. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the second quarter valued at about $78,000. OMERS ADMINISTRATION Corp acquired a new position in CAMP4 Therapeutics in the 4th quarter worth about $115,000. Finally, Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics in the 4th quarter worth about $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.